ESR1 and breast carcinoma: Most ERα+ breast cancer patients will receive 5 years of first-line adjuvant hormone therapy, often in conjunction with CDK4/6 (palbociclib/ribociclib/abemaciclib), mTORC1 (everolimus), or PI3K (alpelisib) inhibitors7.